A dual-responsive doxorubicin–indoximod conjugate for programmed chemoimmunotherapy

Herein we report a dual-responsive doxorubicin–indoximod conjugate (DOXIND) for programmed chemoimmunotherapy. This conjugate is able to release doxorubicin and indoximod upon exposure to appropriate stimuli for synergistic chemotherapy and immunotherapy, respectively. We demonstrate its promoting e...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zhaoxuan, Huang, Jiaqi, Lin, Yaying, Luo, Xiangjie, Lin, Haojin, Lin, Hongyu, Gao, Jinhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: RSC 2022
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257650/
https://www.ncbi.nlm.nih.gov/pubmed/35866166
http://dx.doi.org/10.1039/d1cb00257k
Descripción
Sumario:Herein we report a dual-responsive doxorubicin–indoximod conjugate (DOXIND) for programmed chemoimmunotherapy. This conjugate is able to release doxorubicin and indoximod upon exposure to appropriate stimuli for synergistic chemotherapy and immunotherapy, respectively. We demonstrate its promoting effects on immune response and inhibiting effects on tumor growth through a series of in vitro and in vivo experiments.

Ejemplares similares